Hydrogen Therapy in treatment
of Lung Cancer

Lung cancer is defined as a malignant epithelial neoplasm originating from the bronchial and less commonly from the alveolar epithelium of the lung.

Lung Carcinoma (LC) is the most common malignant solid tumor in both sexes. Non-small cell carcinoma is identified in 85% of cases of lung, with the 5-year survival for patients with stage IV BC being less than 1%.

Already in 1975 a team of scientists discovered that hydrogen inhalations have the potential to be included in treatment strategies, and it is currently believed that Hydrogen Therapy leads to a significant suppression of the proliferation, migration and invasion of cancer cells.

In a controlled clinical trial conducted between June and September 2019. at Fuda Oncology Center of Jinan University, 58 patients with non-small cell carcinoma were enrolled in the study and divided into groups – immunotherapy group, targeted therapy group, chemotherapy group, hydrogen therapy only group, and control group.

From the conducted research, it is clear that hydrogen therapy can double the time during which the patient does not deteriorate (progression free survival) – from 5 months to 10 months. This suggests that hydrogen therapy alone has the potential to halt carcinoma progression.

In addition, hydrogen therapy has led to a significant reduction in the side effects of other types of first-line carcinoma therapy – vomiting and nausea, chest pain, various rashes, dizziness and headache, weight loss, anemia, thrombocytopenia.

Hydrogen therapy also reduced the symptoms associated with lung carcinoma – cough, shortness of breath, hemoptysis, pleural effusion and chest tightness.

From the comparative graph (A and B), between the group without and that with hydrogen therapy, the reduction in symptoms caused by lung carcinoma is clearly seen in the patients undergoing hydrogen inhalation.

Visibly reduced: the cough associated with lung cancer; shortness of breath and easy fatigue; chest pains restricting the breathing process.

In those undergoing hydrogen therapy, the incidence of pleural effusions was also reduced from 30% to almost 5%, and the incidence of blood in sputum was reduced from 20% to almost 0% as early as the fourth month after starting inhalation therapy.

Patients on hydrogen therapy significantly reduced the symptoms caused by lung carcinoma (graph B), while patients in the group without hydrogen therapy showed a stable tendency to increase the frequency of symptoms (graph A).

From the indicated graphs, it is clear that hydrogen therapy with inhalations, applied for 5 months, significantly reduces the percentage of side reactions of the standard treatment of lung cancer – nausea and vomiting, macopapular rash, insomnia and inflammation of the mucous membrane of the oral cavity. which occurs with radiotherapy of lung carcinoma.

The general scientific conclusion made is that inhalation of hydrogen gas every day for 4-5 hours or even 1 hour can significantly improve the general condition and health status of patients with lung carcinoma.

Hydrogen therapy is compatible with modern lung cancer treatment, has a good tolerability profile, and at the same time slows the progression of the oncological disease.

Hydrogen therapy can significantly improve the clinical symptoms of shortness of breath, cough and sputum production in lung cancer patients, as well as the symptoms of nausea, vomiting, dizziness and headache – characteristic of brain metastases.

Here, the fact that hydrogen inhalations are characterized by a good tolerance and safety profile also comes into consideration.